Using two xenograft models of triple‐negative human breast cancer with either wt or mutant p53 status, we demonstrated that reversible inhibition of p53 protects the hearing function, without compromising the anti‐tumor efficacy of CDDP and even sensitizing TP53‐mutant tumors to CDDP. This evidence concerns the gene TP53 and breast cancer.